LE WE PMID CA
Catumaxomab ttEpCAM ttCD3 linkerAb11921Catumaxomab ttEpCAM ttCD3 linkerAb

Abatacept ttCTLA4Conjugate

Abciximab ttGPIIAIIIB

Adalimumab ttTNFalpha

AIN457

Alemtuzumab ttCD52

AMG386 ttAngiopoietin1 ttAngiopoietin2

Antibodies (bispecific)

Antibodies (therapeutic use)

Ascites

Atacicept ttBlys ttAPRIL

Bapineuzumab ttAmyloidBeta

Basiliximab ttIL2R

Belatacept ttCD80 ttCD86

Belimumab ttBLyS

Bevacizumab ttVEGF

Bi20 ttCD20

Blinatumomab ttCD19

Brentuximab vedotin ttCD30

Briakinumab ttIL12 ttIL23

Canakinumab ttIL1beta

Catumaxomab ttEpCAM ttCD3 linkerAb

Certolizumab ttTNFalpha

Cetuximab ttEGFR

Daclizumab ttIL2R

Dalotuzumab ttIGF1R

Denosumab ttRANKL

Eculizumab ttFactorH

Efalizumab ttLFA1

Epratuzumab ttCD22

Ertumaxomab ttHER2

Etanercept ttTNFalpha

FactorIXFc ttFactorIX

FactorVIIIFc ttFactorVIII

Farletuzumab ttFolateRalpha

Gemtuzumab ozogamicin ttCD33

Girentuximab ttCarbonicAnhydraseIX

Golimumab ttTNFalpha

Ibritumomab tiuxentan yttrium ttCD20

Infliximab ttTNFalpha

Ipilimumab ttCTLA4

Motavizumab ttRSVirus

MuromonabCD3 ttCD3

Naptumomab estafenatox tt5T4

Natalizumab ttIntegrinalpha4

Necitumumab ttEGFR

Nimotuzumab ttEGFR

Obinutuzumab ttCD20

Ofatumumab ttCD20

Omalizumab ttCD20

Otelixizumab ttCD3

Pagibaximab ttLipoteichoicAcidStaphlococcus

Palivizumab ttRSVirusFprotein

Panitumomab ttEGFR

Peritoneum (Carcinomatosis)

Pertuzumab ttHER2

Ramucirumab ttVEGFR2

Ranibizumab ttVEGF

Raxibacumab ttAnthrax

REGN88 ttIL6R

Reslizumab ttIL5

Rilonacept ttIL1R

Rituximab ttCD20

Solanezumab ttAmyloidBeta

Stomach (Neoplasia)

T1H ttCD6

Teplizumab ttCD3

Tocilizumab ttIL6

Tositumomab ttCD20

Trastuzumab emtansine ttHER2

Trastuzumab ttHER2

Tremelimumab ttCLTA4

Ustekinumab ttIL12 ttIL23

Vedolizumab ttIntegrina4b7

Zalutumumab ttEGFR

Zanulimumab ttCD4

2011  
1
Antibody-based therapeutics to watch in 2011.
[21051951] MAbs 3(1): 76-99 (2011)
2010  
2
Catumaxomab: clinical development and future directions.
[20190561] MAbs 2(2): 129-36 (2010)
2009  
3
Bispecific antibodies for cancer therapy: the light at the end of the tunnel?
[20073127] MAbs 1(6): 539-47 (2009)
2010  
4
Review of catumaxomab in the treatment of malignant ascites.
[21188120] Cancer Manag Res 2(-): 283-6 (2010)
PMC   
5
Treatment of gastric peritoneal carcinomatosis by combining complete surgical resection of lesions and intraperitoneal immunotherapy using catumaxomab.
[24589307] BMC Cancer 14():148 (2014)

Downloaded from http://www.kidney.de - The Database of Free Medical Reviews - The Metatextbook of Medicine - Ossip Groth

All Medline data shown were primarily retrieved from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.



  • Catumaxomab ttEpCAM ttCD3 linkerAb

  • The BDOM Bibliographic Dictionary of Medicine is a curated collection of free medical articles tagged to concepts.
    Contents until 2011 are reviews from PubMed, contents flagged 'PMC' are regular articles from PubMed Central.
    Search BDOM
    Nephrology Collection
    Radiology Locator

    PubMedCentral monthly collection of free medical articles by major subject

    The framed wikipedia articles are from en.wikipedia.org and they are the actual versions; the first is from Nephropedia